Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population

Current Alzheimer Research

Volumn 11, Issue 1, 2014, Pages 40-46

  Spies, Petra E ^a   Verbeek, Marcel M ^a   Sjögren, Magnus J C ^a   de Leeuw, Frank Erik ^a   Claassen, Jurgen A H R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amyloid beta peptides; Apolipoproteins E; Brain infarction; Cerebrospinal fluid; Dementia; Leukoencephalopathies

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; EPISODIC MEMORY; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; TEMPORAL LOBE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; BRAIN; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; PEPTIDE FRAGMENTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84891777468     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205010666131120101352     Document Type: Article

References (35)

1. Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 33: 1986-92 (2002).
2. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2: 157-61 (1999).
3. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci USA 105: 3587-92 (2008).
4. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283: H315-H323 (2002).
5. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. Beta- Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380: 168-71 (1996).
6. Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke 40: 2601-6 (2009).
7. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-44 (2010).
8. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 66: 245-9 (2009).
9. Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. Stroke 36: 954-9 (2005).
10. Mayeux R, Stern Y, Ottman R Tatemichi TK, Tang MX, Maestre G, et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol 34: 752-4 (1993).
11. Wahlund LO, Barkhof F, Fazekas FBronge L, Augustin M, Sjögren M, Wallin A, Ader H, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32: 1318-22 (2001).
12. Scheltens P, Leys D, Barkhof F Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in probable Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55: 967-72 (1992).
13. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86: 420-8 (1979).
14. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-46 (2007).
15. de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM. Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin Chem Lab Med 45: 1421-34 (2007).
16. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke 26: 1293-301 (1995).
17. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 69: 1850-8 (2007).
18. Schneider JA, Arvanitakis Z, Leurgans SE, Bennet DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66: 200-8 (2009).
19. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26: 699-708 (2011).
20. Marchant NL, Reed BR, DeCarli CS, Madison CM, Weiner MW, Chui HC, et al. Cerebrovascular disease, amyloid, and cognition in aging. Neurobiol Aging 33: 1006-e25-36 (2012).
21. Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, et al. The Aging Brain andCognition: Contribution of Vascular Injury and A to Mild Cognitive Dysfunction. JAMA Neurol 70(4): 488-95 (2013).
22. Van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med 7: e1000245 (2010).
23. Johnston JA, Liu WW, Todd SA, Coulson DT, Murphy S, Irvine GB, et al. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem Soc Trans 33: 1096-100 (2005).
24. Timmer NM, Kuiperij HB, De Waal RM, Verbeek MM. Do amyloid beta-associated factors co-deposit with Abeta in mouse models for Alzheimer's disease? J Alzheimers Dis 22: 345-55 (2010).
25. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54 (2003).
26. Claassen JA, Zhang R. Cerebral autoregulation in Alzheimer's disease. J Cereb Blood Flow Metab 31: 1572-7 (2011).
27. Meel-van den Abeelen AS, Lagro J, van Beek AH, Claassen JA. Impaired Cerebral Autoregulation and Vasomotor Reactivity in Sporadic Alzheimer's Disease. Curr Alzheimer Res 11(1): 11-17 (2013).
28. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 167: 2431-6 (2007).
29. Son SJ, Lee KS, Lee Y, Baek JH, Choi SH, Na DL, et al. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) 4 allele in the elderly: retrospective analysis of data from the CREDOS study. J Clin Psychiatry 73(12): 1555-62 (2012).
30. Schneider JA, Bennett DA. Where vascular meets neurodegenerative disease. Stroke 41: S144-S146 (2010).
31. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-7 (1997).
32. Rieske RG, Leverenz JB, McCormick W, Bowen JD, Teri L, Nochlin D, et al. Effect of Vascular Lesions on Cognition in Alzheimer's Disease: A Community-Based Study. J Am Geriatr Soc 52: 1442-8 (2004).
33. Huang L, Ling XY, Liu SR. Diffusion tensor imaging on white matter in normal adults and elderly patients with hypertension. Chin Med J (Engl) 119: 1304-7 (2006).
34. Kapeller P, Barber R, Vermeulen RJ, Adèr H, Scheltens P, Freidl W, et al. Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke 34: 441-5 (2003).
35. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363: 1139-45 (2004).